These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1015 related items for PubMed ID: 25461318

  • 1. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
    Jiao Y, Xin BT, Zhang Y, Wu J, Lu X, Zheng Y, Tang W, Zhou X.
    Eur J Med Chem; 2015 Jan 27; 90():170-83. PubMed ID: 25461318
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.
    Kim M, Lee J, Jung K, Kim H, Aman W, Ryu JS, Hah JM.
    Bioorg Med Chem Lett; 2014 Aug 01; 24(15):3600-4. PubMed ID: 24878193
    [Abstract] [Full Text] [Related]

  • 3. Design, synthesis and biological activities of sorafenib derivatives as antitumor agents.
    Yao J, He Z, Chen J, Sun W, Fang H, Xu W.
    Bioorg Med Chem Lett; 2012 Nov 01; 22(21):6549-53. PubMed ID: 23021967
    [Abstract] [Full Text] [Related]

  • 4. Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors.
    Yang W, Chen Y, Zhou X, Gu Y, Qian W, Zhang F, Han W, Lu T, Tang W.
    Eur J Med Chem; 2015 Jan 07; 89():581-96. PubMed ID: 25462267
    [Abstract] [Full Text] [Related]

  • 5. Design, synthesis and evaluation of novel diaryl urea derivatives as potential antitumor agents.
    Lu C, Tang K, Li Y, Li P, Lin Z, Yin D, Chen X, Huang H.
    Eur J Med Chem; 2014 Apr 22; 77():351-60. PubMed ID: 24675135
    [Abstract] [Full Text] [Related]

  • 6. Synthesis, biological evaluation and 3D-QSAR studies of novel 4,5-dihydro-1H-pyrazole niacinamide derivatives as BRAF inhibitors.
    Li CY, Li QS, Yan L, Sun XG, Wei R, Gong HB, Zhu HL.
    Bioorg Med Chem; 2012 Jun 15; 20(12):3746-55. PubMed ID: 22583669
    [Abstract] [Full Text] [Related]

  • 7. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
    Wang H, Quan H, Lou L.
    Biochem Biophys Res Commun; 2017 Jul 15; 489(1):14-20. PubMed ID: 28536078
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors.
    Wang SF, Zhu YL, Zhu PT, Makawana JA, Zhang YL, Zhao MY, Lv PC, Zhu HL.
    Bioorg Med Chem; 2014 Nov 01; 22(21):6201-8. PubMed ID: 25267006
    [Abstract] [Full Text] [Related]

  • 9. Design, synthesis and activity of novel sorafenib analogues bearing chalcone unit.
    Wang M, Xu S, Wu C, Liu X, Tao H, Huang Y, Liu Y, Zheng P, Zhu W.
    Bioorg Med Chem Lett; 2016 Nov 15; 26(22):5450-5454. PubMed ID: 27777009
    [Abstract] [Full Text] [Related]

  • 10. Design, synthesis, and biological evaluation of novel imidazole derivatives possessing terminal sulphonamides as potential BRAFV600Einhibitors.
    Ali EMH, Abdel-Maksoud MS, Ammar UM, Mersal KI, Ho Yoo K, Jooryeong P, Oh CH.
    Bioorg Chem; 2021 Jan 15; 106():104508. PubMed ID: 33280830
    [Abstract] [Full Text] [Related]

  • 11. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
    Matsumoto S, Miyamoto N, Hirayama T, Oki H, Okada K, Tawada M, Iwata H, Nakamura K, Yamasaki S, Miki H, Hori A, Imamura S.
    Bioorg Med Chem; 2013 Dec 15; 21(24):7686-98. PubMed ID: 24216091
    [Abstract] [Full Text] [Related]

  • 12. Design and synthesis of novel 2-(4-(2-(dimethylamino)ethyl)-4H-1,2,4-triazol-3-yl)pyridines as potential antitumor agents.
    Qin M, Zhai X, Xie H, Ma J, Lu K, Wang Y, Wang L, Gu Y, Gong P.
    Eur J Med Chem; 2014 Jun 23; 81():47-58. PubMed ID: 24826815
    [Abstract] [Full Text] [Related]

  • 13. Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting V600EBRAF.
    Abdel-Maksoud MS, Ali EMH, Ammar UM, Mersal KI, Yoo KH, Oh CH.
    Bioorg Med Chem; 2020 Jun 01; 28(11):115493. PubMed ID: 32340792
    [Abstract] [Full Text] [Related]

  • 14. [Synthesis and in vitro cytotoxic activities of sorafenib derivatives].
    Wang K, Li Y, Zhang LJ, Yang HZ, Chen XG, Feng ZQ.
    Yao Xue Xue Bao; 2014 May 01; 49(5):639-43. PubMed ID: 25151734
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and biological evaluation of novel 4-(2-fluorophenoxy)-2-(1H-tetrazol-1-yl)pyridines bearing semicarbazone moieties as potent antitumor agents.
    Qin M, Liao W, Xu C, Fu B, Ren J, Gu Y, Gong P.
    Arch Pharm (Weinheim); 2013 Nov 01; 346(11):840-50. PubMed ID: 24114959
    [Abstract] [Full Text] [Related]

  • 16. Structure-based design and synthesis of novel pseudosaccharine derivatives as antiproliferative agents and kinase inhibitors.
    Elsayed MS, El-Araby ME, Serya RA, El-Khatib AH, Linscheid MW, Abouzid KA.
    Eur J Med Chem; 2013 Mar 01; 61():122-31. PubMed ID: 23063746
    [Abstract] [Full Text] [Related]

  • 17. Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAFV600E/p38α inhibitors.
    Ali EMH, El-Telbany RFA, Abdel-Maksoud MS, Ammar UM, Mersal KI, Zaraei SO, El-Gamal MI, Choi SI, Lee KT, Kim HK, Lee KH, Oh CH.
    Eur J Med Chem; 2021 Apr 05; 215():113277. PubMed ID: 33601311
    [Abstract] [Full Text] [Related]

  • 18. Design, synthesis, in-vitro antiproliferative activity and kinase profile of new picolinamide based 2-amido and ureido quinoline derivatives.
    El-Damasy AK, Seo SH, Cho NC, Kang SB, Pae AN, Kim KS, Keum G.
    Eur J Med Chem; 2015 Aug 28; 101():754-68. PubMed ID: 26218653
    [Abstract] [Full Text] [Related]

  • 19. [Design, synthesis and antitumor activity of sorafenib analogues containing 2-picolinylhydrazide moiety].
    Qin AF, Li Y, Song HR, Chen XG, Jin XF, Wang K, Zhang LJ, Huo LC, Feng ZQ.
    Yao Xue Xue Bao; 2012 Dec 28; 47(12):1623-9. PubMed ID: 23460968
    [Abstract] [Full Text] [Related]

  • 20. Identification of type II inhibitors targeting BRAF using privileged pharmacophores.
    Zhang Q, Wang J, Wang F, Chen X, He Y, You Q, Zhou H.
    Chem Biol Drug Des; 2014 Jan 28; 83(1):27-36. PubMed ID: 24164966
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.